Eiger BioPharmaceuticals, Inc.
EIGR
Rang in Aktien
#36392
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aktienkurs
$1.73
Zuletzt synchronisiert: 2025-06-17
Marktkapitalisierung
$2.55M
Veränderung (1 Tag)
-0.29%
Veränderung (1 Jahr)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)
Kategorie
Healthcare
Kursverlauf für Eiger BioPharmaceuticals, Inc. (EIGR)
Höchster Schlusskurs: $8.50 am 2024-10-01
Niedrigster Schlusskurs: $3.75K am 2014-01-01
Niedrigster Schlusskurs: $3.75K am 2014-01-01
Kursverlauf der Aktie von Eiger BioPharmaceuticals, Inc. von 2014 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | 8.23% |
| 2023 | -86.28% |
| 2022 | -65.86% |
| 2021 | -43.34% |
| 2020 | -27.82% |
| 2019 | 28.55% |
| 2018 | -15.78% |
| 2017 | 8.44% |
| 2016 | -45.90% |
| 2015 | -91.44% |
| 2014 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
